Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

MLA

Changjun Wang, et al. “Pyrotinib with Trastuzumab and Aromatase Inhibitors as First-Line Treatment for HER2 Positive and Hormone Receptor Positive Metastatic or Locally Advanced Breast Cancer: Study Protocol of a Randomized Controlled Trial.” BMC Cancer, vol. 20, no. 1, July 2020, pp. 1–6. EBSCOhost, https://doi.org/10.1186/s12885-020-07143-2.

APA

Changjun Wang, Yan Lin, Yidong Zhou, Feng Mao, Hanjiang Zhu, Jinghong Guan, Xiaohui Zhang, Songjie Shen, Xin Huang, Chang Chen, Ru Yao, Jialin Zhao, & Qiang Sun. (2020). Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial. BMC Cancer, 20(1), 1–6. https://doi.org/10.1186/s12885-020-07143-2

Chicago

Changjun Wang, Yan Lin, Yidong Zhou, Feng Mao, Hanjiang Zhu, Jinghong Guan, Xiaohui Zhang, et al. 2020. “Pyrotinib with Trastuzumab and Aromatase Inhibitors as First-Line Treatment for HER2 Positive and Hormone Receptor Positive Metastatic or Locally Advanced Breast Cancer: Study Protocol of a Randomized Controlled Trial.” BMC Cancer 20 (1): 1–6. doi:10.1186/s12885-020-07143-2.